US immunotherapy company Inovio Pharmaceuticals Inc on Wednesday said its experimental vaccine to prevent coronavirus infection was shown to produce protective antibodies and immune system responses in mice and guinea pigs. "We saw antibody responses that do many of the things we would want to see in an eventual vaccine," said Dr.
David Weiner, director of the vaccine and immunotherapy center at the Wistar Institute, which has collaborated with Inovio. "We are able to target things that would prevent the virus from having a safe harbor in the body." Inovio, which began human testing of its vaccine in April, said preliminary results from that trial are expected in June.